Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extended protocol of ranibizumab for rare VEGF-driven ocular diseases
2013-001421-55Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2015
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in Subretinal neovascularization, macular edema, Ocular neovascularization and 3 more, sponsored by Novartis. Primary endpoint: Adverse events, serious and non-serious, ocular and non-ocular. Started Sep 2015; status: completed.
02
Drugs
ranibizumab
03
Conditions
Subretinal neovascularizationmacular edemaOcular neovascularizationIris neovascularization (NVI)neovascular glaucoma (NVG)
Beyond the preview
Go deeper on 2013-001421-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001421-55.